Stryker Co. (NYSE:SYK) Shares Sold by LaFleur & Godfrey LLC

Share on StockTwits

LaFleur & Godfrey LLC reduced its position in Stryker Co. (NYSE:SYK) by 0.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 79,084 shares of the medical technology company’s stock after selling 420 shares during the quarter. Stryker comprises approximately 4.1% of LaFleur & Godfrey LLC’s holdings, making the stock its 5th largest position. LaFleur & Godfrey LLC’s holdings in Stryker were worth $16,258,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Massey Quick Simon & CO. LLC acquired a new position in shares of Stryker during the second quarter worth about $27,000. Cable Hill Partners LLC acquired a new position in shares of Stryker during the first quarter worth about $30,000. Ossiam acquired a new position in shares of Stryker during the second quarter worth about $33,000. Webster Bank N. A. grew its position in shares of Stryker by 300.0% during the second quarter. Webster Bank N. A. now owns 200 shares of the medical technology company’s stock worth $41,000 after buying an additional 150 shares in the last quarter. Finally, Westside Investment Management Inc. acquired a new position in shares of Stryker during the second quarter worth about $47,000. 72.95% of the stock is owned by institutional investors.

SYK stock opened at $221.20 on Friday. The business has a 50 day moving average price of $217.19 and a 200 day moving average price of $200.60. The stock has a market cap of $82.48 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.68 and a beta of 0.83. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $223.45. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.05. The firm had revenue of $3.65 billion during the quarter, compared to analysts’ expectations of $3.60 billion. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.76 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 8.21 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio is currently 28.45%.

In other Stryker news, Director Srikant M. Datar sold 350 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $215.00, for a total value of $75,250.00. Following the completion of the sale, the director now owns 6,844 shares in the company, valued at $1,471,460. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $205.88, for a total value of $960,636.08. Following the completion of the sale, the insider now owns 155,963 shares of the company’s stock, valued at approximately $32,109,662.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,447 shares of company stock valued at $4,359,827. 7.20% of the stock is owned by company insiders.

A number of equities analysts have recently commented on SYK shares. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, July 29th. BMO Capital Markets set a $216.00 price objective on Stryker and gave the stock a “hold” rating in a research report on Friday, July 26th. Piper Jaffray Companies reissued a “buy” rating on shares of Stryker in a research report on Wednesday, September 4th. Raymond James set a $240.00 target price on Stryker and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Credit Suisse Group boosted their target price on Stryker from $232.00 to $237.00 and gave the stock an “outperform” rating in a research note on Friday, July 26th. Five analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Stryker has an average rating of “Buy” and an average price target of $214.89.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: What is a capital gains distribution?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Consolidated Edison, Inc.  Shares Sold by Brookstone Capital Management
Consolidated Edison, Inc. Shares Sold by Brookstone Capital Management
Brookstone Capital Management Acquires 11,346 Shares of iShares Russell 2000 ETF
Brookstone Capital Management Acquires 11,346 Shares of iShares Russell 2000 ETF
Chemung Canal Trust Co. Cuts Stake in Cisco Systems, Inc.
Chemung Canal Trust Co. Cuts Stake in Cisco Systems, Inc.
Tesla Inc  Position Cut by Coastal Investment Advisors Inc.
Tesla Inc Position Cut by Coastal Investment Advisors Inc.
Arlington Partners LLC Sells 15,625 Shares of Procter & Gamble Co
Arlington Partners LLC Sells 15,625 Shares of Procter & Gamble Co
Coastal Investment Advisors Inc. Increases Stock Position in Cree, Inc.
Coastal Investment Advisors Inc. Increases Stock Position in Cree, Inc.


© 2006-2019 Ticker Report